Loading
A phase 3 trial of Pembrolizumab, Olaparib, Etoposide, Carboplatin, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) is a phase 3 interventional study registered as NCT04380636 by Merck Sharp & Dohme LLC, with 870 participants enrolled, started 2020-07-06 and due to reach its primary completion in 2027-05-05. Interventions recorded: Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin and Cisplatin.
Shares Pemetrexed, Merck & Co. (MSD), Cisplatin, Carboplatin and the tag pipeline.
Shares Etoposide, Merck & Co. (MSD), Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Merck & Co. (MSD), Cisplatin, Pembrolizumab and the tag pipeline.